EBI3 (IL-27 subunit) Monoclonal Antibody (ebic6), APC, eBioscience™, Invitrogen™

Description

• EBI3 is a subunit in two distinct heterodimeric cytokines: interleukin-27 (IL-27) and IL-35 (1-3)
• Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines
• It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28
• IL-27 is produced after activation by antigen-presenting cells and induces proliferation of naive but not memory CD4+ T-cells
• It acts by binding to its receptor WSX-1 (also known as TCCR) and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes
• It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet
• IL-35 is composed of EBI3 and the p35 subunit of IL-12 and has been reported to have therapeutic effects against collagen-induced arthritis by expanding the population of regulatory T cells and suppressing Th17 cells
• At least two isoform of EBI3 are known to exist
• EBI3 (IL-27 subunit) Monoclonal antibody specifically detects EBI3 (IL-27 subunit) in Human samples
• It is validated for Flow Cytometry.